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tions in theOPA1gene that promotes fusionof the innermito-
chondrial membrane and plays a role in maintaining ATP
levels. Patients display optic disc pallor, retinal ganglion cell
(RGC) loss and bilaterally reduced vision. We report a ran-
domized, placebo-controlled trial of idebenone at 2000 mg/
kg/day in 56 Opa1 mutant mice (B6;C3-Opa1Q285STOP), with
RGC dendropathy and visual loss, and 63 wildtype mice. We
assessed cellular responses in the retina, brain and liver
and RGC morphology, by diolistic labeling, Sholl analysis
andquantiﬁcation of dendriticmorphometric features. Vision
was assessed by optokinetic responses. ATP levels were
raised by 0.57 nmol/mg (97.73%, p= 0.035) in brain from
idebenone-treated Opa1 mutant mice, but in the liver there
was an 80.35% (p= 0.011) increase in oxidative damage.
NQO1 expression in Opa1 mutant mice was reduced in the
brain (to 30.5%, p= 0.002) but not in retina, and neither
expression levelwas inducedby idebenone.ON-centerRGCs
failed to show major recovery, other than improvements in
secondary dendritic length (by 53.89%, p= 0.052) and den-
dritic territory (by 2.22  104 lm2 or 90.24%, p= 0.074). An
improvement in optokinetic response was observed (by
12.2 ± 3.2 s, p= 0.003), but this eﬀect was not sustained
over time.OFF-centerRGCs from idebenone-treatedwildtype
mice showed shrinkage in total dendritic length by 2.40 mm
(48.05%, p= 0.025) and a 47.37% diminished Sholl proﬁle
(p= 0.029). Visual function in wildtype idebenone-treated
mice was impaired (2.9 fewer head turns than placebo,
p= 0.007). Idebenone appears largely ineﬀective in
protecting Opa1 heterozygous RGCs from dendropathy.http://dx.doi.org/10.1016/j.neuroscience.2016.01.042
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Dominant optic atrophy is a mitochondrial optic
neuropathy that can aﬀect between 1 in 30,000 and 1 in
10,000 people, and manifests as a loss of retinal
ganglion cells and reduction in visual acuity leading to
blindness (Votruba et al., 1998b; Newman and Biousse,
2004). There is no current treatment, although idebenone
has been proposed as a potential therapy (Yu-Wai-Man
et al., 2014). Recently idebenone has been given
approval by the European Medicines Agency for use in
patients with another mitochondrial optic neuropathy,
Leber’s hereditary optic neuropathy (http://www.ema.eu-
ropa.eu/ema/), making a trial of idebenone in dominant
optic atrophy very logical and topical. Patients with
dominant optic atrophy present with reduction in best-
corrected visual acuities ranging from light perception to
20/20 (median 20/120) (Votruba et al., 1998a), and a sub-
set of patients may also develop peripheral neuropathies,
myopathies and sensorineural hearing loss (Yu-Wai-Man
et al., 2010; Chao de la Barca et al., 2015). The majority
of cases derive from dominantly inherited somatic muta-
tions in the optic atrophy locus 1 gene (OPA1) located
on chromosome 3q28 (Eiberg et al., 1994; Alexander
et al., 2000; Delettre et al., 2000) although mutations in
other genes can cause inherited optic neuropathies
resembling dominant optic atrophy (Lenaers et al.,
2012). The OPA1 gene encodes a small GTPase of the
dynamin family, and following the proteolytic cleavage of
the OPA1 protein it functions as a pro-fusion factor in
the inner mitochondrial membrane (Davies and Votruba,
2006; Song et al., 2007; Alavi and Fuhrmann, 2013). Skin
ﬁbroblasts and peripheral blood lymphocytes from
dominant optic atrophy patients reveal reduced levels ofons.org/licenses/by-nc-nd/4.0/).
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fusion and increased mitochondrial ﬁssion (Agier et al.,
2012), with increased susceptibility of these cells to both
apoptosis (Olichon et al., 2007) and oxidative stress
(Zanna et al., 2008; Formichi et al., 2015), and when
OPA1 is depleted by RNA interference there is reduced
mitochondrial DNA content (Elachouri et al., 2011).
Our lab has previously reported a heterozygous
mutant Opa1 mouse, B6;C3-Opa1Q285STOP, hereafter
referred to as BL/6-Opa1+/ (Davies et al., 2007). The
Opa1 heterozygous nonsense mutation c.853C>T,
located in exon 8 immediately before the central
dynamin-GTPase, results in protein truncation and ca.
50% reduction in Opa1 protein expression in retina
(Davies et al., 2007). This Opa1 deﬁciency aﬀects retinal
ganglion cells in an age-dependent manner (Williams
et al., 2010). In mice over 12 months of age, mitochondria
along the dendrites of ON-center retinal ganglion cells
appear fragmented and lose cristae length, and neuronal
dendrites recede and shorten (dendropathy) (Williams
et al., 2010, 2012). At 15 months, PSD-95 immunostain-
ing revealed reduced synaptic density in sublamina b,
the locale where ON-center retinal ganglion cells receive
their inputs (Williams et al., 2012). The dendropathy is
suﬃcient to result in optic nerve degenerative changes
visible on electron microscopy, and reduced visual acuity
and retinal ganglion cell function, documented in
BL/6-Opa1+/ mice by optokinetic testing and retinal
electrophysiology (Davies et al., 2007; Barnard et al.,
2011). In addition to retinal abnormalities, heart tissue
from BL/6-Opa1+/ mice at 12 months showed
decreased ATP levels and Complex I and IV deﬁciencies
in mitochondria (Chen et al., 2012).
Idebenone is a synthetic benzoquinone and
structurally very similar to ubiquinone, a key component
in the mitochondrial respiratory chain (Gueven et al.,
2015). Idebenone is soluble in oral preparations and
suﬃciently lipophilic to permeate cellular membranes
(Erb et al., 2012), and is reduced via two-electron transfer
to the hydroquinone form by NAD(P)H:quinone
oxidoreductase-1 (NQO1, Haefeli et al., 2011). This
reduction step is critical in its ability to transfer electrons
to Complex III of the mitochondrial respiratory chain,
and in turn maintain mitochondrial membrane potential
and rescue ATP levels in tissue-cultured cells
compromised with the Complex I inhibitor rotenone
(Haefeli et al., 2011; Erb et al., 2012; Giorgio et al.,
2012). Idebenone is known to inhibit lipid peroxidation
and is a powerful antioxidant (Suno and Nagaoka, 1984;
Erb et al., 2012). In a mouse model of Huntington’s dis-
ease, idebenone delayed the development of cardiac
hypertrophy (Seznec et al., 2004). However, idebenone
can promote formation of superoxide radicals under cer-
tain conditions and its mode of action is incompletely
understood (King et al., 2009).
Human clinical studies have shown high doses of
idebenone are well tolerated, with only minor
gastrointestinal complaints, and correlate with modest
clinical score improvements in patients with Friedreich’s
ataxia and Leber’s hereditary optic neuropathy (Di
Prospero et al., 2007; Bodmer et al., 2009; Kutz et al.,2009; Carelli et al., 2011; Klopstock et al., 2011;
Parkinson et al., 2013; Buyse et al., 2015). A small uncon-
trolled, open-label case series in seven dominant optic
atrophy patients using idebenone at doses of between
270 mg and 1000 mg per day over one year found that
two of the patients reported no subjective visual improve-
ments, although the overall mean visual acuity from the
cohort did improve and in four patients did so bilaterally
(Barboni et al., 2013). A reduction in scotoma size and
greater color discrimination and retinal nerve ﬁber layer
thickness was evident, albeit disparate between individu-
als likely owing to patients recruited at diﬀerent stages of
disease, having varied mutations, ages, and idebenone
dosages given (Barboni et al., 2013). Understandably,
these clinical data are insuﬃcient to justify the use of ide-
benone and further data are needed to underpin a full clin-
ical trial of idebenone in human disease.
Our aim in this study, the ﬁrst to use idebenone in an
experimental mouse model of dominant optic atrophy,
was to undertake a randomized, placebo-controlled trial
in BL/6-Opa1+/ mice. Our trial design was chosen to
mirror a potential trial of idebenone in human patients,
in patients receiving treatment at or following clinical
diagnosis. We treated BL/6-Opa1+/ mice from the time
of the onset of retinal ganglion cell degeneration, and
report on its eﬀects and therapeutic potential.
EXPERIMENTAL PROCEDURES
Ethical statement
All mice were housed in a secure facility and maintained
under constant temperature (22 C) and humidity (45–
65%) on a 12 h day/12 h night cycle, with access to
water and solid food ad libitum (2014 Teklad Global
14% protein rodent maintenance diet) in accordance
with the Animal (Scientiﬁc Procedures) Act 1986. One
week prior to the start of the trial, mice were singly
housed in large, adjacent cages with environmental
enrichment. They were then kept singly housed
throughout the days of the trial.
Idebenone preparations, dosing and trial design
Idebenone(6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-
1,4-benzoquinone), marketed as Raxone in the
treatment of Leber’s hereditary optic neuropathy,
was obtained through a material transfer agreement
with Santhera Pharmaceuticals (Lot 080091) and
prepared as a 20 mg/ml stock solution in 0.5%
carboxymethycellulose salt (SIGMA) by overnight
stirring at 4 C. In line with other authors, we found mice
would only eat idebenone-laced rations when it was
mixed with sugar. Heitz et al. (2012) used 4% sucrose
in regular chow (Heitz et al., 2012), however the mice in
our colony did not accept this (even at 8% sucrose).
Therefore it was necessary to mix idebenone with jelly.
Hartley’s Jelly was melted and mixed with idebenone
(135 g in a ﬁnal volume of 190 ml), and food rations equiv-
alent to 2000 mg per kg mice body weight were pipetted
into weighboats and stored at 20 C for 1 month (initial
and third-week mouse weights were used to calculate
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135 g jelly mixed with only 0.5% carboxymethycellulose
salt (to a ﬁnal volume of 190 ml).
The trial included 119 mice (generation 5–7 on
C57BL/6J background), with 63 wildtype (38 male and
25 female) and 56 BL/6-Opa1+/ mutant mice (25 male
and 31 female) randomly assigned into four groups;
wildtype and BL/6-Opa1+/ mice that received either
idebenone or placebo rations. Mice were 12 to
14 months (365 to 420 days) old at the start of the 60-
day protocol and dendropathy and cellular assessments
(ATP and oxidative stress) were primary endpoints. A
second cohort of mice were on average 11 months old
at the start of the 42-day protocol for visual assessment
and NQO1 analysis. Mice were supplied a single ration
each day for 42 or 60 consecutive days, and the daily
consumption of each ration was recorded. Mice were
weighed 1 week before the start of the trial, and
thereafter every week until completion. Non-fasting
blood glucose concentration tests were performed with
an Accu-Chek kit from Roche between 10 a.m. and 2
p.m. with blood sampled from the heart chamber
following sacriﬁce. Non-fasting blood glucose
concentration from age-matched wildtype mice only fed
standard chow was also taken. We processed mice in
small groups (average n= 6) to remove bias arising as
a result of tissue preparation time. The brain and liver
were removed for molecular assays, and retinas were
ﬂat-mounted for retinal ganglion cell labeling.Genotyping
DNA samples of ear tissue were immersed in 50 ll of
50 mM sodium hydroxide and heated to 95 C for
10 min. Samples were then neutralized with 10 ll of 1 M
TrisHCl pH 7.0, vortexed and spun. 1 ll was used as a
template in a PCR reaction of 35 cycles with annealing
temperature 59 C with the following primers to detect
the mutant allele; forward 50-TCTCTTCATG
TATCTGTGGTCTTTG-30, and reverse 50-TTACCCGTG
GTAGGTGATCATA-30.Molecular assays
Sagittal quartered brain and liver tissue samples were
snap frozen in liquid nitrogen and stored at 80 C.
Samples for lipid peroxidation studies were held under
argon gas at 80 C in a sealed glass bottle.
For the ATP assay, brain and liver samples were
processed to extract ATP according to the
manufacturer’s instructions (Abcam, Cambridge, UK).
Brieﬂy, tissue was homogenized and then deproteinated
in ice-cold 4 M perchloric acid. Following neutralization,
samples were spun and the supernatant, containing
ATP, collected. Assays were performed using a 96-well
plate and absorbance read at 570 nm after 60 min
incubation at room temperature. Readings were
compared to ATP standards provided in the kit. Five
microliter of the homogenate was tested separately in a
BCA assay (SIGMA) to determine the amount of tissue
protein used in the ATP assay.Brain tissue samples for the thiobarbituric acid
reactive species (TBARS) assay were homogenized in
1X butylated hydroxytoluene and lysis buﬀer (Abcam,
Cambridge, UK). It was important to spin samples and
carefully pipette supernatant free from cellular debris
before and after an incubation of 95 C for 1 h with
thiobarbituric acid (reconstituted in glacial acetic acid).
Readings were taken at 540 nm in a BioTek plate
reader. Readings were compared to malondialdehyde
standards provided with the kit. A sample of the
homogenate was taken to determine protein
concentration as above.Protein carbonyl assay and western blotting
Protein from mouse liver samples were homogenized in
RIPA lysis buﬀer containing protease inhibitor cocktail
(Sigma–Aldrich) and 2% 2-mercaptoethanol (Sigma–
Aldrich). Protein carbonyl groups were measured with
the OxyBlotTM protein oxidation detection kit (Merck
Millipore, Nottingham, UK) following the manufacturer’s
instructions. 20 lg of total protein was separated on a
10–12% SDS–PAGE gel and transferred to a
nitrocellulose membrane (Biorad, Hemel Hempstead,
UK). Protein samples were incubated with blocking
buﬀer (1% (w/v) bovine serum albumen in PBS pH
7.2–7.4) for 1 h at room temperature. A rabbit anti-2,
4-dinitrophenylhydrazone antibody (1:150) was applied
in blocking buﬀer for 1 h at room temperature. After
washing in 0.05% Tween-20, a goat anti-rabbit
horseradish peroxidase secondary antibody was used at
1:300 for 1 h at room temperature and blots developed
using the enhanced chemiluminescence detection kit
(Biological Industries, Lichﬁeld, UK) and Pierce CL-
XposureTM Film (Thermo Scientiﬁc, Paisley, UK).
Western blotting was performed on 20 lg total protein
and ran on 10–14% SDS–PAGE gels. Protein was
extracted from individual mouse brain and liver samples,
and from retina samples pooled from 4 mice. A mouse
anti-OPA1 antibody (BD Biosciences), rabbit anti-NQO1
(Abcam, Cambridge, UK), and mouse anti-actin
(SIGMA) were used at 1/1000 overnight at 4 C to probe
for OPA1, NQO1 and actin protein. Following four
washes, rabbit anti-mouse and goat anti-rabbit
horseradish peroxidase secondary antibodies (SIGMA)
were used at 1/2000 and 1/2000, respectively, at room
temperature for 2–4 h before being developed as above.
Bands from multiple western blots were quantiﬁed
using ImageJ software and normalized to actin for
relative values (as percent change relative to wildtype).Visual function assessment
We followed the EMPReSS method (http://empress.har.
mrc.ac.uk/) to record optokinetic responses. Three and
six weeks from the start of feeding idebenone or
placebo, mice were placed on a platform within a drum
and allowed to habituate in the dark for 10 min.
Thereafter, mice spent 5 min in light before testing
began. We used a spectroradiometer to set the
illuminance to 250 candela at the level of the platform.
The drum was rotated clockwise for 1 min, and after a
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for 1 min. Mice activity was recorded using a video
camera and later assessed for the optokinetic response.
The inner surface of the drum was lined with black-and-
white stripes set at 1 cm intervals (representing 2 or
0.25 cycles/deg of visual arc), and was the highest level
of resolution BL/6-Opa1+/ mice could detect (Davies
et al., 2007). Mice that are able to detect the moving grat-
ing will begin moving their head in the same direction and
with the same speed as the drum before turning back. We
counted the total number of these head turns for both
clockwise and counter-clockwise directions, and the total
time the mice actively spent tracking. These tests were
repeated three times in total with 3 min of rest in the dark
between each test. Each mouse was tested on three sep-
arate days to generate a large number of observations for
reliable quantiﬁcation. Video ﬁles were anonymized by
assigning them six-digit numerical IDs and assessed by
two independent researchers.Immunohistochemistry
Ten micrometer cryosections of brain and liver tissue
samples, and 12 lm sections of retina were thawed in
PBS and then boiled in citrate buﬀer pH 6.0 for 30 min.
Slides were cooled to room temperature, washed in
PBS with 0.1% Tween-20 and 0.1% Triton-X100, and
then blocked for 1–2 h at room temperature in 10% fetal
bovine serum. 1/400 anti-NQO1 antibody was applied in
5% fetal bovine serum overnight at 4 C, washed three
times before 1/500 anti-rabbit Alexa secondary antibody
was applied. Slides were incubated in 1/500 TO-PRO-
3 (Life Technologies, Paisley, UK) for 5 min before
being washed in PBS and mounted in ProLong Gold
under a #1 coverslip (Life Technologies, Paisley, UK)
mountant.Retinal cell labeling and morphometric analysis
Retinal ganglion cells were DiOlistically labeled using a
Helios Gene Gun (Bio-Rad) and imaged with a confocal
microscope Zeiss (LSM 510, 20, 0.8 N.A lens)
(Williams et al., 2010). Serial slices were captured at a
resolution of 1024  1024 pixels and taken at 0.4 lm
incremental steps.
Each retinal ganglion cell image stack was copied and
then randomly assigned 6-digit identiﬁers generated from
www.random.org. In this way retinal ganglion cells could
be traced without bias by two operators blinded to their
origin. The simple neurite tracer plugin for ImageJ was
used to delineate the dendrites of retinal ganglion cells
and resulted in a dendritic skeleton for each that
mapped to their dendritic tree. All imaged retinal
ganglion cells were veriﬁed with the presence of an
axon. The depth to which dendrites ramify in the inner
plexiform layer was used to determine ON- (0–60%)
versus OFF- (60–100%) retinal ganglion cells (Coombs
et al., 2006). Following tracing, each ﬁle was then de-
coded and assorted into bins for each condition and geno-
type for further analysis.
Sholl analysis is a widely used measure of the
complexity of retinal ganglion cell dendritic architecture(Sholl, 1953), and has been used as a sensitive readout
of the earliest physical evidence of retinal damage in glau-
coma (El-Danaf and Huberman, 2015). In our study, inter-
sections were counted across 10 lm concentric rings up
to a range of 470 lm. A trapezoidal calculation method
was used to measure the area under each Sholl curve.
The total dendritic length was calculated as the sum of
all the individual paths from the tracing skeleton. For the
dendritic territory, a straight-sided polygon was traced
around the terminal ends of dendrites and the resulting
area calculated within ImageJ. Individual primary, sec-
ondary and tertiary dendrites were identiﬁed from their
corresponding traced skeleton. The branching index
was calculated as in (Garcia-Segura and Perez-
Marquez, 2014). Instead of taking negative values as
zero, we separated positive and negative data to reﬂect
the overall increase or decrease in branching,
respectively.
Retinal ganglion cells’ eccentricities were measured
using the stage controller stepper attached to the
microscope (Zeiss). The location of the optic nerve head
was manually aligned and set at 0.00 lm.Statistics
Values are expressed as mean ± SEM. Statistical
signiﬁcance between groups was estimated by one
sample, single-tailed Student’s t-tests, with Bonferroni
correction where necessary, and values of 6p= 0.05
were considered signiﬁcant. Power calculations were
performed in R, and for the treatment arm a sample
number of n= 14 was suﬃcient to give us a power of
0.8 for changes as small as 15% for most metrics. Two-
step cluster analysis was performed in SPSS Statistics
22.RESULTS
Idebenone administration in a mouse model of
dominant optic atrophy
The logistics of the trial we conducted is summarized in
Fig. 1A. There were three protocols based on a 21-day,
42-day and 60-day timeline to measure and assess
various molecular, cellular and physiological eﬀects as
outlined. The analysis was based on per-protocol
treatments, deﬁned by a P75% consumption of planned
dose density achieved. For P75% dose density, mice
had to eat at least 90% of their ration for at least 75% of
the time (i.e., 16 days out of 21, 32 days out of 42, and
45 days out of 60). Our per protocol strategy speciﬁed
doses within tight parameters in all mice so that the
outcome of all four arms of the trial could be compared.
During the course of treatment, eleven mice did not
achieve the planned minimum dose density (of these,
nine were from the wildtype idebenone arm of the trial).
Four mice died during the course of the trial. Therefore
our analysis was conducted on a total of 104 mice
(Fig. 1B).
In brain tissue samples from BL/6-Opa1+/ mice,
expression levels of Opa1 protein were reduced by
33.02% (Cv 0.13, p= 0.044) (Fig. 1C, D), consistent
Fig. 1. Overview of placebo-controlled idebenone trial in BL/6-Opa1+/ mice. (A) Male and female mice at 12 to 14 months of age were randomly
assorted into four groups: wildtype treated and untreated, and BL/6-Opa1+/ treated and untreated. Mice were fed idebenone per day for 21, 42 or
60 days. (B) Per protocol treatment chart showing the number of mice which ate their rations for the indicated completion of the trial. Fifteen mice
were excluded from the trial. (C) Representative western blot for Opa1 protein (actin control) from brain tissue. (D), Densitometry of placebo-fed
wildtype (n= 6) and BL/6-Opa1+/ mutant mice (n= 4), and from idebenone-fed BL/6-Opa1+/ mutant mice (n= 6). (E) Mean non-fasting blood
glucose levels taken from wildtype and BL/6-Opa1+/ mice at time of death. (F) Weekly weight of surviving male mice (wildtype n= 33; BL/6-
Opa1+/ n= 16), and female mice (wildtype n= 18; BL/6-Opa1+/ n= 18). Dashed lines above and below male plots show the diﬀerence in
weight of mice that had either placebo or idebenone in their rations. Week 0 is weight before start of the trial.
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Opa1+/ models (Alavi et al., 2007; Davies et al., 2007;
Sarzi et al., 2012). Opa1 protein levels did not change
from baseline after idebenone treatment (Fig. 1D).
To assess if there were any eﬀects from the diet
administered, we measured weekly body weight and
non-fasting blood glucose levels at the end of the
testing period. Wildtype mice in the trial fed placebo
rations had a mean non-fasting blood glucose level of
155.81 mg/dL (152.34 mg/dL for those wildtype mice fed
idebenone-laced rations) and BL/6-Opa1+/ mice fed
placebo rations had a mean non-fasting blood glucoselevel of 151.05 mg/dL (Fig. 1E). When compared to
wildtype animals at 10 to 12 months of age fed only
standard chow, which had a non-fasting mean blood
glucose concentration of 159.3 mg/dL (data not shown),
we found there was no signiﬁcant eﬀect incurred from
the increased sugar in the diet. The mean non-fasting
blood glucose concentration for BL/6-Opa1+/ mice fed
idebenone was reduced to 136.92 mg/dL, and was
signiﬁcantly diﬀerent from wildtype mice administered
with idebenone (p= 0.012), or on placebo rations
(p= 0.004) (Fig. 1E). No mouse had a blood glucose
concentration in the range of 200–450 mg/dL, values
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diabetes research (Wu et al., 2001; Barber et al., 2005;
Lee et al., 2006; Zhang et al., 2011). Additionally, across
8 weeks of the trial the weight of both male and female
mice remained stable (Fig. 1F). Wildtype males were sig-
niﬁcantly heavier than their BL/6-Opa1+/ mutant litter-
mates by 16.5% or 5.0 g (Fig. 1F, p 6 0.05, Bonferonni
correction). There were no statistically signiﬁcant
diﬀerences in weight between female wildtype and
BL/6-Opa1+/ mutant littermates. Consumption of
idebenone-laced rations over placebo produced only a
small diﬀerence in weight between wildtype male mice
(Fig. 1F), but not so BL/6-Opa1+/ mutants (Fig. 1F) or
between female mice (data not shown).
Diﬀerences exist between male and female brain ATP
levels in BL/6-Opa1+/mice
All data on ATP levels came from the brains of the same
mice whose retinal explants were used in the dendropathy
study. The baseline level of ATP in brain tissues relative
to total tissue protein in 14 to 16-month-old placebo-fed
wildtype mice was 4.52 nmol/mg (95% CI 4.20 to 4.85,
Cv 0.13; Fig. 2A), which is consistent with previous
reports (Gkotsi et al., 2014). In male BL/6-Opa1+/
mutant brain tissue, baseline ATP levels were
5.41 nmol/mg (95% CI 4.41 to 6.41, Cv 0.15,
p= 0.051). By contrast, in female BL/6-Opa1+/ mutant
brain tissue we found a modest but signiﬁcant reductionFig. 2. Idebenone does not aﬀect ATP levels in BL/6-Opa1+/ mice but does
female mice were assessed for ATP levels per mg tissue protein in pla
idebenone-fed BL/6-Opa1+/ mice (n= 12). Absolute values are shown fo
mean ± SEM. Brackets show mean for male and female separately. (B), Brai
wildtype (n= 8) and BL/6-Opa1+/ mice (n= 5), or idebenone-fed BL/6-O
carbonyl groups (actin control marked by asterisk) from liver tissue. (D) Den
mice (n= 3), and idebenone-fed BL/6-Opa1+/ mutant mice (n= 4). *p< 0down to 3.93 nmol/mg (95% CI 3.55 to 4.40, Cv 0.12,
p= 0.042) (as indicated in Fig. 2A). The diﬀerence in
baseline ATP levels between male and female heterozy-
gous brain tissue was statistically signiﬁcant (p= 0.002).
We found that female BL/6-Opa1+/mutant mice on a
60-day regimen of 2000 mg/kg per day of idebenone
showed an increase in ATP levels to 4.50 nmol/mg
(95% CI 4.04 to 4.96, Cv 0.13, p= 0.035; as indicated
in Fig. 2A) as compared to untreated mice. Recovery of
ATP levels in ß-islet cells could promote insulin release
and be responsible for the reduced blood glucose levels
seen in treated BL/6-Opa1+/ mice (Fig. 1E) (Zhang
et al., 2011).
However, we planned our trial to analyze data from
male and female mice inclusively, and overall we found
that BL/6-Opa1+/ mutant mice fed on a 60-day
regimen of 2000 mg/kg per day of idebenone showed
no change in ATP levels as compared to untreated mice
(Fig. 2A).
Idebenone-treated BL/6-Opa1+/ mice exhibit
increased levels of protein carbonylation
We tested for products downstream of lipid peroxidation,
such as malondialdehyde, using a traditional TBARS
assay (Fig. 2B). However we did not ﬁnd any signiﬁcant
diﬀerences between wildtype and BL/6-Opa1+/ mutant
mice (Cv 0.48, p= 0.108), or for an eﬀect of idebenone
(Cv 0.22, p= 0.127). There was no change in lipidinduce superoxide formation. (A) Brain samples from both male and
cebo-fed wildtype (n= 12) and BL/6-Opa1+/ mice (n= 11), and
r males in squares and females in circles, horizontal bars represent
n samples were tested for lipid peroxidation derivatives in placebo-fed
pa1+/ mice (n= 8). (C), Representative western blot for protein
sitometry of placebo-fed wildtype (n= 4) and BL/6-Opa1+/ mutant
.05, **p 6 0.01.
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(Piquereau et al., 2012).
When we tested for protein carbonyl groups, formed
as a result of increased oxidative stress, we found no
signiﬁcant diﬀerences between wildtype and BL/6-
Opa1+/ mutant mice (Fig. 2C, D). However, in the
presence of idebenone, treated BL/6-Opa1+/ mutant
mice displayed a signiﬁcant 80.35% increase in the
levels of protein carbonylation (Cv 0.14, p= 0.011)
(Fig. 2D).Idebenone does not signiﬁcantly reduce the extent of
retinal ganglion cell dendropathy in BL/6-Opa1+/
mice
Labeled retinal ganglion cells from mice in all four arms of
the trial were analyzed and included both ON-center
(Fig. 3A–L) and OFF-center types (Fig. 4). These cells
were sampled from various eccentricities across the
retina to provide an accurate reﬂection of overall health
status (Fig. 3Q). As expected from previous work
(Williams et al., 2010), ON-center retinal ganglion cells
from BL/6-Opa1+/ mice showed a signiﬁcant deteriora-
tion of 51.91% in dendritic complexity (Cv 0.49,
p= 0.007, Fig. 3M, P), total dendritic length was
2.30 mm shorter (Cv 0.51, p= 0.017; Fig. 3R), and den-
dritic territory was reduced by 2.46  104 lm2 (Cv 0.54,
p= 0.008; Fig. 3S) when compared to wildtype. The
branching index analysis (BI) found the positive BI fell
by 0.70  103 (Cv 0.65, p= 0.041) and the negative com-
ponent was reduced by 2.49x103 (Cv 0.60, p= 0.008)
(Fig. 3T), suggesting a more severe dendritic reduction
in secondary and tertiary branches of BL/6-Opa1+/
mutant retinal ganglion cells. We found that secondary
branches in BL/6-Opa1+/ ON-center retinal ganglion
cells were reduced more than primary and tertiary
branches in those cells, and by 0.91 mm compared to
wildtype retinal ganglion cells (Cv 0.59, p= 0.009;
Fig. 3U).
In BL/6-Opa1+/ mutant mice treated with idebenone,
we saw an upward and rightward shift in the Sholl proﬁle
(Fig. 3N), with 22.35% recovery in the area under the
curve compared to untreated BL/6-Opa1+/ mice
(denoted by i in Fig. 3P). However, this result was not
statistically signiﬁcant (Cv 0.97, p= 0.157). There was
improved total dendritic length, being 1.14 mm longer
than it otherwise would have been (Fig. 3R), and
dendritic territory was greater by 2.22 x 104 lm2
(Fig. 3S). The branching index was higher (positive by
0.55  103, negative by 1.42  103, Fig. 3T). However
this was not statistically signiﬁcant for total dendritic
length (p= 0.159) or branching index (positive
p= 0.133, negative p= 0.115), although for average
dendritic territory there was a trend toward improvement
(p= 0.074) (see below).Idebenone may oﬀer some protection to secondary
dendritic branches and dendritic territory in BL/6-
Opa1+/ mutant mice
When we identiﬁed primary, secondary and tertiary
dendrites and plotted their values separately we found asmall beneﬁcial eﬀect of idebenone (Fig. 3U). In ON-
center retinal ganglion cells from idebenone-treated
BL/6-Opa1+/ mice, the accumulative dendritic length
for primary, secondary and tertiary dendrites was
increased over untreated mice by 0.31 mm, 0.49 mm,
and 0.33 mm, respectively. For secondary dendrites this
was equivalent to 53.89% of the actual loss of
secondary dendritic length in BL/6-Opa1+/ retinal
ganglion cells (Cv 0.78, p= 0.052). While these data do
not reach signiﬁcance, they suggest a potential
therapeutic eﬀect of idebenone. We also noted that the
secondary branch length (1.10 mm) and dendritic
territory (4.61  104 lm2, Fig. 3S) of retinal ganglion
cells from idebenone treated BL/6-Opa1+/ mice have
similar values to those found in wildtype mice (1.52 mm
and 4.85  104 lm2, respectively). Comparing untreated
wildtype and treated BL/6-Opa1+/ retinal ganglion cells
as an indicator of therapeutic beneﬁt, we see no
statistically signiﬁcant diﬀerences in dendritic territory
(p= 0.129) (Fig. 3S) or secondary dendritic length
(p= 0.139) (Fig. 3U), suggesting that idebenone may
have a protective eﬀect, suﬃcient to allow the
idebenone-treated BL/6-Opa1+/ retinal ganglion cells
to retain these aspects of their dendritic architecture.Idebenone has signiﬁcant deleterious eﬀects on
wildtype retinal ganglion cells and visual function
The Sholl proﬁles for labeled ON- and OFF-center retinal
ganglion cells from wildtype mice given idebenone
showed a signiﬁcant fall of 38.49% (Cv 0.57, p= 0.030)
and 47.37% in area under the curve (Cv 0.57,
p= 0.029), respectively (Figs. 3O, P, 4C, D). This was
also reﬂected in OFF-center wildtype retinal ganglion
cells by calculating the branching index. Idebenone
caused the positive BI to fall by 1.37  103 (Cv 0.73,
p= 0.003) and the negative BI to fall by 2.99x103 (Cv
0.65, p= 0.009) (Fig. 4E). We also saw a reduction in
the total dendritic length for ON- and OFF-center retina
ganglion cells, with deterioration of 1.61 mm (Cv 0.58,
p= 0.054) and 2.40 mm (Cv 0.55, p= 0.025),
respectively (Fig. 3R, 4F). In addition, idebenone caused
a reduction in the dendritic territory (down by 1.87x104
lm2, Cv 0.65, p= 0.029) in ON-center retinal ganglion
cells (Fig. 3S).
This detrimental eﬀect of idebenone appears to be
reﬂected in the visual function as assessed by
optokinetic response. In wildtype mice fed idebenone,
we saw no signiﬁcant reduction in total tracking time but
the total number of head turns was signiﬁcantly reduced
to 9.2 ± 0.7 compared to placebo wildtype mice
(p= 0.007, Fig. 5B).In an early phase of the disease idebenone restored
vision in BL/6-Opa1+/ mice but this eﬀect was not
sustained
We determined visual function in mice following an
optokinetic response protocol by assessing the head
turning reﬂex, in which mice will turn their head in the
direction of a moving grating and track for a length of
time (Fig. 5A). On average placebo-fed wildtype mice
Fig. 3. Idebenone fails to signiﬁcantly alter dendritic complexity in BL/6-Opa1+/ ON-center retinal ganglion cells. (A–D), representative retinal
ganglion cell labeled with DiI (shown in yellow) from (A) wildtype mice, (B) BL/6-Opa1+/ mice, (C) wildtype mice given idebenone (D) BL/6-Opa1+/
 mice treated with idebenone. (E–H), xz view of stack, counterstained with TO-PRO-3 to show retinal layers. (I–L), Compiled z-stack images of
traced retinal ganglion cell dendrites. Circles show cell body of retinal ganglion cell, with solid line indicating location of axon. Scale bar = 50 lm.
(M–O) Sholl proﬁle showing dendritic complexity for ON-center retinal ganglion cells. (M) comparison between wildtype (n= 12 from 7 mice) and
BL/6-Opa1+/ (n= 11 from 5 mice) cells from mice given placebo. (N) comparison between BL/6-Opa1+/ cells from mice given placebo or treated
with idebenone (n= 14 from 6 mice). (O) Comparison of cells from wildtype mice given placebo or administered with idebenone (n= 13 from 6
mice). (P) The area under the curve for each Sholl plot is shown as percent change relative to wildtype. Dashed lines show the diﬀerence in area
between BL/6-Opa1+/ retinal ganglion cells and those from BL/6-Opa1+/ mice treated with idebenone. i marks potential recovery caused by
idebenone. (Q) The eccentricity of all retinal ganglion cells analyzed in the study. (R) The total dendritic length from ON-center retinal ganglion cells
is shown for each condition, and likewise for, (S) the dendritic territory and (T) the branching index. (U) The dendritic lengths of primary (those
dendrites that originate at soma), secondary (originate from primary dendrites) and tertiary dendrites are shown. *p< 0.05, **p 6 0.01. ns = not
signiﬁcant i.e., p> 0.05. GLC, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. Idebenone has deleterious eﬀects for wildtype OFF-center retinal ganglion cells. (A) A representative OFF-center retinal ganglion cell with
DiI demarcating dendrites and soma. Scale bar = 50 lm. (B) xz view across the retina. (C) Sholl plot comparison between OFF-center retinal
ganglion cells taken from placebo-fed wildtype mice (n= 12 from 6 mice) and idebenone-fed wildtype mice (n= 10 from 5 mice). (D) The area
under the curve for each Sholl plot is shown as percent change relative to wildtype. (E) Separated values for positive and negative branching index.
(F) Measurements of the sum total of dendritic length for each retinal ganglion cell. *p< 0.05, **p 6 0.01.
100 T. G. Smith et al. / Neuroscience 319 (2016) 92–106performed 12.1 ± 0.9 head turns (Fig. 5B) for a total 33.3
± 2.3 s (Fig. 5C) during the testing period (both clockwise
and counter-clockwise directions). In placebo-fed BL/6-
Opa1+/ mice there were fewer turns (7.8 ± 0.6,
p< 0.01) and a reduced tracking time (25.7 ± 1.9 s,
p= 0.007), which is comparable to our previous
published report (Davies et al., 2007). Feeding BL/6-
Opa1+/ mice idebenone did not appreciably aﬀect the
number of head turns (8.1 ± 0.6) but did show an appar-
ent improvement in total tracking time (30.1 ± 2.5 s). This
result did not reach signiﬁcance.
However, when we looked at the tracking time from
3 weeks after the start of the trial, mice did show a
substantial improvement in tracking time (by 12.2 ± 3.2
s, p= 0.003; dashed upper bar in Fig. 5C) and an
increase in the number of head turns (by 1.75 ± 0.8,
p= 0.048; dashed bar in Fig. 5B). In contrast, by
6 weeks after the start of the trial, the vision in BL/6-
Opa1+/ mice had deteriorated to a total of 20.1 ± 2.9
s (dashed lower bar in Fig. 5C), similar to pre-treatment
levels. The diﬀerence in tracking time between 3 weeks
and 6 weeks was very signiﬁcant (p< 0.01).
The expression of NQO1 protein in response to
idebenone is variable and tissue-speciﬁc
We performed expression analysis on brain, retina and
liver tissue samples from our 42-day protocol of
idebenone administration. In brain, both wildtype and
BL/6-Opa1+/ mice have some cells that express
NQO1 protein in the cytoplasm (Fig. 6A), and in retina
NQO1 protein is found within the ganglion cell layer as
well as the inner segment of the photoreceptive layer
(Fig. 6D). In BL/6-Opa1+/ mice liver, NQO1 protein isrobustly expressed in most parenchymal cells (Fig. 6G).
Western blotting from mice fed idebenone or placebo
revealed that NQO1 protein is dynamically expressed in
diﬀerent tissues. In BL/6-Opa1+/ brain tissue, NQO1
protein is expressed 69.5% less than in wildtype brain
(p= 0.002, Fig. 6B, C), and while idebenone induced a
higher expression of NQO1 protein in wildtype brain (by
24.2%, p= 0.027), it did not do so in BL/6-Opa1+/
mice fed idebenone (Fig. 6C). Idebenone substantially
induced NQO1 protein expression in wildtype liver tissue
as well (by 719.7%, p= 0.0003, Fig. 6H, I). In contrast
to brain, BL/6-Opa1+/ liver showed higher NQO1
expression (by 776.1%, p= 0.037, Fig. 6I). In the retina
there were no signiﬁcant diﬀerences in the level of
NQO1 protein, either due to genotype or treatment
condition (Fig. 6E, F).DISCUSSION
We present data on the ﬁrst trial of idebenone in a mouse
model of dominant optic atrophy. Our mutant mouse
model shows very clear morphometric abnormalities in
ON-center retinal ganglion cell dendrites that prove
invaluable indices to accurately quantify the eﬀect of
treatment with idebenone. The importance of dendritic
morphology as a structural marker underlying vision is
highlighted by a recent study that has used these
metrics to assess the earliest indicators of glaucoma
(El-Danaf and Huberman, 2015). Assessment of dendritic
morphology has also been used to measure the eﬀective-
ness of other therapeutic agents following optic nerve
crush (Lindsey et al., 2015a,b). In fact, perturbations to
functional receptive ﬁelds and electrophysiology readings
Fig. 5. Visual assessment of mice shows a temporary improvement in vision after short idebenone exposure. (A) Drum was lined with 1 cm black-
and-white stripes and rotated clockwise (shown here) or counter-clockwise. (B) The number of head turns for both directions during the 42-day
protocol are shown. (C) The total time spent tracking in both directions during the 42-day protocol are shown. Inset dashed lines show the respective
values obtained mid-way through the protocol and at its end. (D) Schematic relating the age between human patients and our mouse model with
respect to retinal disease (http://rubinlab.bgu.ac.il/mouseAPK/H2M/index.html). We used the search term ‘‘retinal degeneration,” which gave a
Pearson correlation of 0.50. The start point of our trial and key times when mice were assessed are shown. 120 human years is the limit of the
database, and therefore the 14 to 16 months protocol is not shown. **p 6 0.01. ns = not signiﬁcant i.e., p> 0.05.
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found to occur concomitantly with structural changes in
dendrites, speciﬁcally the dendritic length, dendritic terri-
tory and Sholl proﬁle (Della Santina et al., 2013). Our
results suggest that idebenone has a small measurable
eﬀect in protecting certain retinal ganglion cell dendritic
parameters, speciﬁcally the length of the secondary
branches and dendritic territory. However, overall there
is little statistically signiﬁcant beneﬁt on retinal ganglion
cell dendropathy, casting doubt on the potential of idebe-
none to restore normal function after the onset of disease
in our mouse model.
The route of administration could have hindered the
therapeutic eﬀect of idebenone, and questions arise
around the appropriate dose and how to achieve it. Oral
administration of idebenone invariably results in rapid
ﬁrst-pass metabolism by the liver and severely reduced
and short-lived plasma concentrations (Bodmer et al.,
2009; Kutz et al., 2009; Becker et al., 2010). In mice, a
single dose of idebenone at 60 mg/kg delivered by
gavage resulted in a maximum concentration peak of
9 ng/ml (26.6 nM) and 37.4 ng/ml (110.5 nM) in the
vitreous and aqueous humor, respectively, but falling to
levels below the limit of quantiﬁcation after just 30 min
and 120 min, respectively (Heitz et al., 2012). Manyexperiments conducted on in vitro cultured cells use
idebenone concentrations at 10,000 nM (even to
100,000 nM in some cases), and it is where many authors
have apparently demonstrated the eﬀectiveness of idebe-
none in restoring various cellular functions (Suno and
Nagaoka, 1984; Heitz et al., 2012; Fiebiger et al., 2013).
The question of whether we should have opted for higher
doses of idebenone to increase concentration at target
sites is an important one, considering values in aqueous
humor were shown to rise proportionally in response to
increasing the amount of idebenone (Heitz et al., 2012).
However it is clear that idebenone can produce measur-
able eﬀects at even lower concentrations in tissue-
cultured cells. Heitz et al. have shown that 10 nM was
the minimum concentration of idebenone required to
rescue rotenone-compromised RGC-5 cells (Heitz et al.,
2012). Importantly these values were also obtained in
mouse vitreous and aqueous humor following 21 days of
idebenone given as a food supplement at a dosage of
2000 mg/kg per day (Heitz et al., 2012). Our choice of a
2000 mg/kg per day dosage is therefore supported by
the literature and likely to be more than suﬃcient to
produce biologically signiﬁcant eﬀects.
In addition, expression and activity of NQO1 are
important prerequisites for any treatment plan involving
Fig. 6. Expression level of NQO1 protein is tissue-speciﬁc and determines the extent of idebenone’s therapeutic eﬀect. (A, D, G) Immunohis-
tochemistry showing tissue-speciﬁc NQO1 expression in brain, retina and liver. Scale bar = 50 lm. (B ,E, H) Representative western blots for
NQO1 (actin as control) in brain, retina and liver tissue. (C) Densitometry of brain samples from placebo-fed wildtype (n= 2) and BL/6-Opa1+/
mutant mice (n= 2), and idebenone-fed BL/6-Opa1+/ mutant mice (n= 2). F), Densitometry of pooled retina samples from placebo-fed wildtype
(n= 4) and BL/6-Opa1+/ mutant mice (n= 4), and idebenone-fed BL/6-Opa1+/ mutant mice (n= 4). (I) Densitometry of liver samples from
placebo-fed wildtype (n= 2) and BL/6-Opa1+/mutant mice (n= 2), and idebenone-fed BL/6-Opa1+/mutant mice (n= 2). *p< 0.05. **p 6 0.01.
ns = not signiﬁcant i.e., p> 0.05. GLC, ganglion cell layer; INL, inner nuclear layer; IS, inner segment; ONL, outer nuclear layer.
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NQO1 protein expression in response to idebenone, as
well as in the expression of NQO1 protein in BL/6-
Opa1+/ mice. The levels of NQO1 protein were
reduced in brain samples from BL/6-Opa1+/ mice, and
this would necessarily limit the potential beneﬁt of
idebenone in this tissue. Others have discussed
implications of a combinatorial therapy whereby NQO1
expression in target tissues could be upregulated using
compounds that promote its transcription via Nrf2 (Jaber
and Polster, 2015). This would increase availability of
NQO1 in neurons and we would expect it to enhance ide-
benone’s electron carrier role.
In retina, NQO1 protein levels remain unchanged
between wildtype and BL/6-Opa1+/ mice, and retinal
ganglion cells expressed NQO1 as shown previously
(Heitz et al., 2012). Therefore in our trial of idebenone ina mouse model of dominant optic atrophy, the reported
actions of idebenone were not a limiting factor.
Our cellular analysis uncovered a negative eﬀect of
idebenone on retinal ganglion cell health in wildtype mice
without a mitochondrial deﬁcit. This was unexpected,
since idebenone has been shown to prevent cultured
neuronal cells from glutamate-induced excitotoxicity and
amyloid ß-peptide-induced neurotoxicity (Hirai et al.,
1998; Fiebiger et al., 2013), and can protect male
Sprague-Dawley rats from kainic acid-induced intrastriatal
neuronal degeneration in vivo(Miyamoto andCoyle, 1990).
Nonetheless, both ON- and OFF-center retinal ganglion
cells from wildtype mice treated with idebenone displayed
a profound deterioration in their dendritic morphology.
This accumulative deleterious eﬀect could be due to
oxidative stress. Interestingly, idebenone is suﬃcient to
indirectly induce the expression of NQO1 in wildtype
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caused increased cellular stress. NQO1 is induced in
the liver via the Nrf2 transcription factor as part of an
antioxidant defense mechanism (Jaber and Polster,
2015; Cheng et al., 2015).
At high concentrations idebenone is known to inhibit
Complex I activity (Esposti et al., 1996), and even cause
the opening of the permeability transition pore complex
(Walter et al., 2000). There are inhibitory eﬀects of non-
reduced idebenone on ATP synthesis and oxygen con-
sumption rate (Giorgio et al., 2012). Idebenone can also
bind to the hydrophobic quinone-binding site of Complex
I and promote superoxide formation (King et al., 2009).
These are all potential mechanisms for how idebenone
could prove detrimental in treated mice, suﬃcient to
reverse any initial, positive recovery. Recently, idebenone
has been shown to inhibit activity of a calcium-activated
chloride channel (Seo et al., 2015), which is expressed
in axon terminals of bipolar cells (Jeon et al., 2013). In a
human prostate cancer cell line and a cystic ﬁbrosis pan-
creatic line, this inhibitory function resulted in cell death
(Seo et al., 2015). If idebenone caused apoptosis in reti-
nal neurons in a similar manner, this could have serious
repercussions for those retinal ganglion cells that receive
input from bipolar axons. Thus it may be that the exact
dosage of idebenone is critical.
In order to evaluate whether the dendropathy seen in
wildtype mice results in a functional eﬀect on vision we
assessed visual function by the optokinetic response
(Davies et al., 2007). As expected we were able to con-
ﬁrm that BL/6-Opa1+/mutant mice displayed reduced
visual function. The dendropathy see in OFF-center
retinal ganglion cells from wildtype mice treated with
idebenone was signiﬁcant. The number of head turns
documented in wildtype idebenone mice was statistically
reduced as compared to wildtype placebo mice, although
when assessing total time spent tracking this signiﬁcance
was lost, suggesting that the eﬀect on visual function may
be borderline.
Nonetheless, our study highlights a possible risk of
using idebenone to treat patients with a misdiagnosis of
mitochondrial optic neuropathy (e.g., dominant optic
atrophy without OPA1 mutation), or in treating patients
with preclinical or subclinical disease. This potential for
visual toxicity in unaﬀected eyes suggests caution will
be needed until it can be shown that this does not result
in or hasten visual loss.
In addition, we show diﬀerences between the genders
of BL/6-Opa1+/ mice that will need to be considered in
planning future studies in mice or man. This diﬀerence
became evident when we looked at ATP levels in
mutant brain tissue. While it could be argued that this
ﬁnding is not clinically important, as there are no clear
gender diﬀerences in morbidity for patients with
dominant optic atrophy, this strongly suggests that
future studies will need to stratify treatments by the
gender of subjects.
Based on the ﬁndings of our dendropathy study, we
measured visual function mid-way through the trial and at
the end, in order to assess the time course of any
potential eﬀect of idebenone. We discovered after a shortduration of idebenone treatment an improvement in the
vision of BL/6-Opa1+/ mice, but this positive eﬀect was
reduced to pre-treatment levels in a short span of three
weeks. This runs counter to the reported ﬁndings in
Friedreich’s ataxia, where a longer duration is associated
with improved clinical scores (Parkinson et al., 2013).
It is well established that mouse life-span and aging is
not linearly correlated to human life-span. The age-
phenome knowledge database (http://rubinlab.bgu.ac.
il/mouseAPK/H2M/index.html) models the relationship
between mouse and human age based on speciﬁc
disease classes (Geifman and Rubin, 2013). When we
correlate the human age to the equivalent age of mice
at the start of our trial, we noted that we began the
60-day protocol at the equivalent human age of 55 years
old, and the 42-day protocol at a human age of 25 years
old. Therefore the age at which medication is adminis-
tered may be critical to treatment eﬀect in patients. In
the 42-day protocol, the administration of idebenone at
a younger age may have contributed to apparent improve-
ment in visual function. This ﬁts well with the time-limited
eﬀects modeled in neurodegenerative disease progres-
sion (Porciatti and Ventura, 2012). From the age phe-
nome theoretical model it is suggested that the 60-day
administration of idebenone is hypothetically equivalent
to more than 65 years of human life, thereby suggesting
that we did administer the drug for an appropriately long
period of time.
Idebenone is currently authorized in the EU as a
treatment option for the mitochondrial optic neuropathy,
Leber’s hereditary optic neuropathy, which results from
mitochondrial DNA mutations in Complex I genes
(Yu-Wai-Man et al., 2014). The ability of idebenone to
restore mitochondrial function under Complex I deﬁciency
has been demonstrated in mice (Heitz et al., 2012). How-
ever, the aberrant mitochondrial eﬀects that result from
OPA1 mutations are more varied than in Leber’s heredi-
tary optic neuropathy, with alternative roles for OPA1
including the regulation of thermogenesis and
ß-oxidation (Quiros et al., 2012), the mediation of cell
apoptosis through inhibiting cytochrome c release
(Varanita et al., 2015), and in the response to cell starva-
tion (Patten et al., 2014). These diﬀerences in pathophys-
iology may explain why idebenone is not equally eﬀective
in both disorders.
In summary, we have carried out a randomized
placebo-controlled trial of idebenone in a mouse model
of dominant optic atrophy. We have found some
indication of therapeutic improvement with idebenone
fed to mice at 2000 mg/kg per day from 11 months
(335 days) of age. Initially, we found that a functional
assessment of vision revealed a large improvement in
visual acuity. After six weeks of treatment, visual acuity
decreased to pre-treatment levels. Starting idebenone
treatment at 12–14 months of age for 60 days showed
only a slight indication of beneﬁt, with the secondary
dendritic length and dendritic territory in BL/6-
Opa1+/mutant ON-center retinal ganglion cells being
greater following idebenone administration. Overall
however, idebenone did not alter the course of the
retinal ganglion cell dendropathy.
104 T. G. Smith et al. / Neuroscience 319 (2016) 92–106In OFF-center retinal ganglion cells from wildtype
retina, idebenone caused a severe reduction in retinal
ganglion cell morphometric parameters, and this was
mirrored by a reduced number of head turns in the
optokinetic response functional visual assessment.
Therefore, although idebenone may be a therapeutic
option in the treatment of some mitochondrial optic
neuropathies, our data suggest it should be used with
caution in individuals where there is no mitochondrial
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